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Aims As promising compounds to lower Lipoprotein(a) (Lp(a)) are emerging, the need for a precise characterization and
comparability of the Lp(a)-associated cardiovascular risk is increasing. Therefore, we aimed to evaluate the distribution of
Lp(a) concentrations across the European population, to characterize the association with cardiovascular outcomes and to
provide high comparability of the Lp(a)-associated cardiovascular risk by use of centrally determined Lp(a) concentrations.
...................................................................................................................................................................................................
Methods
and results
Based on the Biomarkers for Cardiovascular Risk Assessment in Europe (BiomarCaRE)-project, we analysed data
of 56 804 participants from 7 prospective population-based cohorts across Europe with a maximum follow-up of
24 years. All Lp(a) measurements were performed in the central BiomarCaRE laboratory (Biokit Quantia Lp(a)-
Test; Abbott Diagnostics). The three endpoints considered were incident major coronary events (MCE), incident
cardiovascular disease (CVD) events, and total mortality.
We found lower Lp(a) levels in Northern European cohorts (median 4.9 mg/dL) compared to central (median 7.9 mg/
dL) and Southern European cohorts (10.9 mg/dL) (Jonckheere–Terpstra test P < 0.001). Kaplan–Meier curves showed
the highest event rate of MCE and CVD events for Lp(a) levels >_90th percentile (log-rank test: P < 0.001 for MCE and
CVD). Cox regression models adjusted for age, sex, and cardiovascular risk factors revealed a significant association
of Lp(a) levels with MCE and CVD with a hazard ratio (HR) of 1.30 for MCE [95% confidence interval (CI) 1.15–
1.46] and of 1.25 for CVD (95% CI 1.12–1.39) for Lp(a) levels in the 67–89th percentile and a HR of 1.49 for MCE
(95% CI 1.29–1.73) and of 1.44 for CVD (95% CI 1.25–1.65) for Lp(a) levels >_ 90th percentile vs. Lp(a) levels in the
lowest third (P < 0.001 for all). There was no significant association between Lp(a) levels and total mortality.
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Subgroup analysis for a continuous version of cube root transformed Lp(a) identified the highest Lp(a)-associated risk
in individuals with diabetes [HR for MCE 1.31 (95% CI 1.15–1.50)] and for CVD 1.22 (95% CI 1.08–1.38) compared
to those without diabetes [HR for MCE 1.15 (95% CI 1.08–1.21; HR for CVD 1.13 (1.07–1.19)] while no difference
of the Lp(a)- associated risk were seen for other cardiovascular high risk states. The addition of Lp(a) levels to a prog-
nostic model for MCE and CVD revealed only a marginal but significant C-index discrimination measure increase
(0.001 for MCE and CVD; P < 0.05) and net reclassification improvement (0.010 for MCE and 0.011 for CVD).
...................................................................................................................................................................................................
Conclusion In this large dataset on harmonized Lp(a) determination, we observed regional differences within the European
population. Elevated Lp(a) was robustly associated with an increased risk for MCE and CVD in particular among in-
dividuals with diabetes. These results may lead to better identification of target populations who might benefit
from future Lp(a)-lowering therapies.
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Introduction
Lipoprotein(a) (Lp(a)) consists of apolipoprotein(a) and apolipopro-
tein B-100 and has a similar structure both to LDL-cholesterol and to
plasminogen.1,2 Therefore, Lp(a) has a proatherogenic and a pro-
thrombotic component, and is associated with the pathogenesis of
cardiovascular (CV) disease.3,4 Elevated Lp(a) levels were proven as a
marker of increased cardiovascular risk in numerous epidemiological
and genetic studies during the past decades.5–8 Due to the lack of se-
lective Lp(a)-lowering therapies the use of Lp(a) in clinical practice
remains scarce. Recently, new compounds with the potential to
lower Lp(a) like PCSK9-antibodies or the phase 2 study-proved
IONIS-Apo(a) Rx, an antisense oligonucleotide targeting hepatic
apo(a) mRNA,9,10 are presently evaluated in clinical trials. Therefore,
the need for a precise characterization of the Lp(a)- associated CV
risk is of increasing importance. For this purpose comparability of
Lp(a) among different studies is essential.11,12 Although the largest
meta-analysis revealed no significant differences among various meth-
ods of Lp(a) determination, it remains unclear whether the observed
variability between studies was due to regional differences or due to
the use of different assays.6 Further, underlying datasets should offer
sufficient power to perform a diversity of subgroup analyses, in order
to identify those individuals at highest Lp(a)-associated risk.
To achieve a more comparable as well as precise and timely char-
acterization of the Lp(a)-associated CV risk in Europe we aimed to
analyse the harmonized data of centrally measured Lp(a) of 7 cohorts
from 5 European countries with 56 804 individuals and a maximum
follow-up time of 24 years within the Biomarker for Cardiovascular
Risk Assessment in Europe (BiomarCaRE) project.13
Methods
Study overview
The design and rationale of the BiomarCaRE project have been described
previously in detail.13 Briefly, BiomarCaRE is based on the MORGAM
(MONICA Risk Genetics Archiving and Monograph) Project.14 The
MORGAM/BiomarCaRE Data Center in Helsinki harmonized individual
data from 21 population-based cohort studies with central storage of se-
lected biomaterial of more than 300 000 participants in the central
BiomarCaRE laboratory in Hamburg. All presented Lp(a) concentrations
were measured centrally at this laboratory site using the same Lp(a) assay.
Local ethics review boards approved all participating studies.
Study cohorts
The present analysis included data of 7 cohorts from 5 European coun-
tries comprising 56 804 individuals with available Lp(a) levels from 52 131
individuals. Cohorts involved were the FINRISK Study and the
DanMONICA Study as Northern European cohorts, the Caerphilly
Prospective Study and the Kooperative Gesundheitsforschung in der
Region Augsburg (KORA) Study as Central European cohorts, and the
MONICA Brianza Study, the MATISS cohort (Rome) and the Moli-Sani
Project as Southern European cohorts. Each cohort is based on a well-
defined population (see Supplementary material online, Table S1).
Cohort descriptions are provided in Supplementary material online, Box
S1.
For each cohort, the following harmonized variables were available at
baseline: age, sex, body-mass-index (BMI), systolic blood pressure, lipid-
lowering medication, anti-hypertensive medication, smoking status, his-
tory of diabetes, total cholesterol, low-density lipoprotein cholesterol
(LDL), high-density lipoprotein cholesterol (HDL). LDL and HDL were
not available for the Caerphilly Prospective Study. History of diabetes
was defined as documented or self-reported, or diagnosed diabetes.
Anti-hypertensive medication and smoking status were self reported.
BMI, systolic blood pressure, and lipid parameters have been measured
values. LDL cholesterol was calculated using the Friedewald formula.
Study outcome
We defined the following outcome measures: (i) first fatal or non-fatal
major coronary event (MCE) including the definite, possible, definite or
possible (if not specifiable) acute myocardial infarction, coronary death,
unstable angina pectoris, and cardiac revascularization, (ii) first major car-
diovascular disease (CVD) event including the first fatal or non-fatal cor-
onary heart disease event or likely cerebral infarction, coronary death,
unstable angina pectoris, cardiac revascularization, ischaemic stroke, and
unclassifiable death, and (iii) total mortality defined as mortality due to
any cause during follow-up. Detailed endpoint definitions are in
Supplementary material online.
Laboratory procedures
All Lp(a) measurements were performed in the central BiomarCaRE la-
boratory between 2011 and 2015 using a fully automated, particle-
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..enhanced turbidimetric immunoassay (Biokit Quantia Lp(a)-Test; Abbott
Diagnostics, USA). This assay is not affected by apo(a) size heterogen-
eity.15 The limit of detection (LOD) is 0.38 mg/dL. Measurements are lin-
ear in the range of 1.3–90.0 mg/dL. Intra-assay coefficients of variation
were <4% and inter-assay coefficients of variation were <9% for each co-
hort (see Supplementary material online, Table S3). The further included
lipid parameters were measured locally at each participating centre.
Statistical methods
Associations between baseline variables like total cholesterol, smoking
status, hypertension, BMI, diabetes, sex (male), age at baseline examin-
ation, storage time, and Lp(a) concentrations were assessed using
Spearman correlations. These were computed using mixed effects mod-
els combining individual participant data as described by Pigott and col-
leagues.16 This allowed us to consider cohort heterogeneity. Lp(a)
concentrations >90 mg/dL were defined as 90 mg/dL.
For prediction of a first ever MCE, CVD event, and total mortality,
only participants without a prior history of major CVD such as myocar-
dial infarction (MI), hospitalized unstable angina, coronary artery bypass
grafting, percutaneous transluminal coronary angioplasty, or ischaemic or
haemorrhagic stroke were included.
Survival curves for MCE, CVD events, and total mortality were com-
puted according to Lp(a) categories, using thirds and the 90th percentile,
adapted from Kamstrup and colleagues.11 The last cut-off allowed to dif-
ferentiate the risk for high and very high Lp(a) values. Furthermore, we
performed additional analyses for Lp(a) levels >_50 mg/dl vs.<50 mg/dL
which is the suggested cut-off according to the ESC guidelines.7,17 These
predefined categories were applied in the overall BiomarCaRE cohort.
Sex- and cohort-stratified Cox proportional hazards models for MCE,
CVD events, and total mortality were computed using the individual level
data from the available cohorts. For these analyses, Lp(a) was used after
applying the cubic root transformation as a continuous variable and using
pre-defined categories mentioned above. The Cox models for all three
endpoints were adjusted in Model 1 for age as time scale, sex as strata
and cohort as strata, and in Model 2 additionally for classical cardiovascu-
lar risk factors (smoking status, arterial hypertension, BMI, history of dia-
betes, total cholesterol, and age as time scale). We corrected LDL
cholesterol and total cholesterol for the Lp(a) contribution according to
the compositional data of Lp(a) with a cholesterol proportion of 30%.18
Therefore, Lp(a) was multiplied by 0.3 and this term was subtracted from
LDL cholesterol and total cholesterol for each individual as done by pre-
vious studies.11 Since there was a substantial number of missing values re-
garding intake of lipid-lowering medication in the KORA and Caerphilly
cohorts we did not adjust for this variable in the main outcome analysis
but performed separate analyses with additional adjustment for intake of
lipid-lowering medication in all cohorts except KORA and Caerphilly.
We classified subjects taking antihypertensive medication as being
hypertensive. We examined the association between Lp(a) concentra-
tions and time to event in different subgroups (age < 65 years vs. age >_ 65
years, men vs. women, daily smoker vs. non-daily smoker, diabetes vs. no
diabetes, hypertension vs. no hypertension, BMI < 30 vs. BMI >_ 30,
Southern, central Europe vs. Northern Europe, and LDL < 160 mg/dL vs.
LDL >_ 160 mg/dL). The previous models were extended by adding an
interaction term between Lp(a) and subgroup indicator. This allowed to
estimate subgroup specific Lp(a) hazard ratios and to test if the hazard
ratios in the two categories of the subgroup variable were different. No
adjustment for multiple testing was performed due to the exploratory na-
ture of the analyses.19
The C-index20 and the net reclassification improvement (NRI)21,22
were used to quantify the added predictive value of Lp(a) beyond that
from a model including classical risk factors. For the computation of NRI
follow-up times were censored at ten years. Ten-fold cross validation
was used to control for the over-optimism of calculating performance
measures on the same dataset from which the models were computed.
The risk categories used for the NRI analysis were <1%, 1 to <5%, 5 to
<10%, and >_10%23 for MCE, CVD, and total mortality. A version of NRI
appropriate for survival analyses was computed using the Kaplan–Meier
method.22 The overall NRI does not represent a proportion and is there-
fore reported as a decimal number between -2 and 2 rather than a
percentage, as recommended by Leening and colleagues.21 Differences in
C-statistics (with 95% CIs) after the addition of Lp(a) to the model con-
sisting of cardiovascular risk factors were computed using the method
described by Antolini and colleagues.24
A two-sided P-value of <0.05 was considered statistically significant. All
statistical methods were implemented in R statistical software version
3.2.2 (www.R-project.org).
Results
Baseline characteristics
Baseline characteristics for the overall study population are shown in
Table 1, of each individual cohort in Supplementary material online,
.................................................................................................
Table 1 Baseline characteristics of the study
population
Characteristics
Number of cohorts, N 7
Number of individuals, N 56 804
Years of baseline examinations, range in years 1986 - 2008
Men, N (%) 28 498 (50.2)
Women, N (%) 28 306 (49.8)
Age at baseline examination, y 52.4 (42.1, 62.0)
Cardiovascular risk factors
Daily smokers, N (%) 13 304 (23.8)
Diabetes, N (%) 3063 (5.4)
Hypertension, N (%) 27 233 (48.1)
Body mass index, kg/m2 26.7 (24.0, 29.8)
Systolic blood pressure, mmHg 134.0 (121.0, 150.0)
Total cholesterol, mg/dL 215.0 (189.0, 245.0)
HDL cholesterol, mg/dL 54.0 (45.0, 65.0)
LDL cholesterol, mg/dL 122.0 (98.0, 147.0)
Medication
Antihypertensive, N (%) 11 340 (20.3)
Cholesterol lowering, N (%) 2357 (5.2)
Lipoprotein (a)
Information on lipoprotein (a), N (%) 52 131 (91.8)
Lipoprotein (a), mg/dL 8.7 (3.9, 19.1)
Endpoints during follow-up
Major coronary event, N (%) 2452 (4.5)
Cardiovascular disease, N (%) 2966 (5.5)
Total mortality, N (%) 4877 (9.0)
Baseline characteristics are presented as absolute and relative frequencies for cat-
egorical variables, and quartiles for continuous variables as well as range in years
for years of baseline examinations. Numbers of endpoints during follow-up are
reported for individuals without CVD at baseline.
HDL, high density lipoprotein; LDL, low density lipoprotein.
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Table S1, and according to predefined categories of Lp(a) levels in
Supplementary material online, Table S2.
Men and women were equally distributed (49.8%, n = 28 306 fe-
male subjects). The median age was 52.4 years. Study participants
were slightly overweight (median BMI 26.7 kg/m2) and median sys-
tolic blood pressure was 134 mmHg. At baseline, 23.8% of the study
cohort were daily smokers, 48.1% were diagnosed with hyperten-
sion, and 5.4% had diabetes. The median values for LDL-cholesterol,
total cholesterol, and HDL-cholesterol at baseline were 122 mg/dL,
215 mg/dL, and 54 mg/dL, respectively.
Distribution and correlations of Lp(a)
Lp(a) was measured in 91.8% (52 131 of 56 804) of study participants.
The distribution of Lp(a) was skewed to the right in the overall co-
hort with a median of 8.7 mg/dL (IQR 3.9 to 19.1 mg/dL), a mean of
15.8 mg/dL [standard deviation (SD) 18 mg/dL] and the 66th, and
90th percentiles at 14.1 mg/dL and 43.5 mg/dL, respectively (Figure 1).
We found a trend towards lower Lp(a) levels in the Northern
European cohorts with an Lp(a) median of 4.9 mg/dL compared to an
Lp(a) median of 10.9 mg/dL in Southern Europe (see Supplementary
material online, Figure S2). To test if the gradient in median Lp(a) con-
centrations among North, Central, and South European populations
is statistically significant, we performed Jonckheere–Terpstra test
which resulted in P-value <0.001.25 Detailed illustrations of the distri-
bution of Lp(a) of Northern, Central, and Southern European co-
horts and for each particular cohort are shown in Supplementary
material online, Figure S1.
In the overall cohort total cholesterol and age at baseline corre-
lated positively with Lp(a) levels whereas male sex, diabetes, and BMI
correlated negatively with Lp(a) levels. All correlations were only
modest in nature (Table 2). Hypertension, smoking status, and stor-
age duration as a technical variable did not correlate significantly with
Lp(a) levels.
Outcome analysis
Two thousand four hundred and fifty-two incident MCE were
observed during a median follow-up time of 8.8 years, 2966 incident
CVD events after a median of 8.7 years, and 4877 deaths after a me-
dian of 9.2 years.
As illustrated in the Kaplan–Meier survival analyses across the pre-
defined categories of Lp(a) levels MCE and CVD event rates
increased with increasing Lp(a) levels with the highest event rates in
the upper third of the distribution. No significant association between
Lp(a) categories and all-cause mortality was observed (Figure 2).
Cox regression analyses revealed a significant association of Lp(a)
with incident MCE such as Lp(a) levels between the 66th and 90th
percentile were associated with a HR of 1.30 compared to the lowest
third (95% CI 1.15–1.46) P < 0.01) after adjustment for a broad spec-
trum of risk factors (Figure 3, Models 1 and 2). Individuals with Lp(a)
levels above the 90th percentile had the highest risk for future MCE
with a HR of 1.49 (95% CI 1.29–1.73). Similar results were obtained
when addressing a broader definition of CVD endpoints (Figure 3),
whereas no significant association was found for total mortality.
Further adjustment for lipid-lowering medication did not change the
observed associations appreciably (data not shown).
Corresponding analyses for the clinically recommended threshold
of Lp(a) >_50 mg/dL vs. <50 mg/dL revealed comparable results for all
investigated endpoints (see Supplementary material online, Figures S3
and S4). Cox regression analyses for Lp(a) treated as a continuous
variable and the three outcome measures as well as regional stratified
analysis by cohort and sorted by European region are displayed in
Supplementary material online, Figures S5 and S6.
Subgroup analysis of the Lp(a)-associated
risk
Results of subgroup analyses of the Lp(a)-associated risk are shown
in Figure 4. Hazard ratios for cube root transformed Lp(a) were com-
parable across various predefined subgroups except for individuals
with diabetes. For these individuals, the Lp(a)-associated risk was
higher (HR for MCE 1.31, for CVD 1.22, and for total mortality 1.15)
compared to individuals without diabetes (HR for MCE 1.15, for
CVD 1.13, and for total mortality 0.96). In individuals in other cardio-
vascular high risk states, e.g. smoking, hypertension, LDL >_160 mg/dL
or obesity (BMI >_30 kg/m2) there was no relevant difference of the
Lp(a)-associated risk compared to individuals without these cardio-
vascular high-risk states (Figure 4).
Importantly, despite regional differences of Lp(a) levels across
Europe with lower Lp(a) levels in Northern European cohorts, the
Lp(a)-associated risk in Northern European cohorts was comparable
to the Lp(a)-associated risk in Central and Southern European
cohorts.
Lp(a) and prediction of major coronary
events, cardiovascular disease events,
and total mortality
Assessing C-statistics for prediction of MCE, CVD events, and total
mortality we observed marginal but significant changes for MCE and
CVD events and no changes for total mortality after the addition
of Lp(a) to the base model (see Supplementary material online,
Table S4).
Figure 1 Density of Lp(a) levels in the entire study population.
Density (y-axis) of Lp(a) levels (x-axis) in the entire study popula-
tion including 52 131 measurements. Each column indicates the
density of an Lp(a) range of 1 mg/dL. The median, 33th, 66th, 80th,
and 90th percentiles are marked separately.
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..Reclassification analyses after the addition of Lp(a) to a model con-
sisting of cardiovascular risk factor (CVRF) variables are presented in
Supplementary material online, Table S5. The addition of Lp(a) to the
CVRF variables for MCE led to an NRI of 0.010 (95% CI -0.008 to
0.028), 0.006 (95% CI -0.011 to 0.023) for cases and 0.004 (95% CI
0.002 to 0.006) for non-cases. The addition of Lp(a) to the CVRFs al-
gorithm for CVD events produced an NRI of 0.011 (95% CI
from -0.006 to 0.028), 0.008 (95% CI -0.008 to 0.024) for cases and
0.003 (95% CI 0.001 to 0.005) for non-cases and almost no improve-
ment for total mortality. Reclassification tables showing estimates of
the expected number of reclassifications per risk category for cases
and non-cases are provided in the Supplementary material online,
Table S5.
Discussion
Based on a harmonized large scale assessment of Lp(a) and cardiovas-
cular outcome the main study findings are: (i) Lp(a) distribution has a
north–south gradient with lower Lp(a) levels in Northern European
populations compared to Central or Southern European popula-
tions. (ii) We confirm Lp(a) as a marker of cardiovascular risk in the
European population with an particular increase of the Lp(a)-
associated risk for MCE and CVD events above the 66th and the
90th percentile. (iii) The Lp(a)-associated risk was particularly
observed in individuals with diabetes compared to those without
diabetes.
Regional distribution of Lp(a) levels
across Europe
It is well known that Lp(a) levels vary strongly between ethnicities.26
However, because different Lp(a) assays lack precise comparability,
differences of Lp(a) levels across individual participants from large-
scale datasets have not yet been described in-depth. Our results
showing lower Lp(a) levels in Northern European countries are con-
sistent with a small cohort study measuring Lp(a) in 2164 participants
older than 70 years from different regions of Europe.27 Furthermore,
we observed a 0.582 fold lower Lp(a) median in the Finnish FINRISK
cohort compared to the Lp(a) median in the German KORA cohort.
....................................................................................................................................................................................................................
Table 2 Spearman correlations of Lp(a) and CV risk factors
Total
cholesterol
Daily
smokers
Hyper-
tension
BMI Diabetes Sex
(male)
Age at
baseline
Storage
time
Correlation coefficient for Lp(a), 0.04 -0.02 0.01 -0.02 -0.02 -0.07 0.06 -0.01
P-value P < 0.001 P = 0.061 P = 0.090 P = 0.0033 P < 0.001 P < 0.001 P < 0.001 P = 0.29
Spearman correlations of lipoprotein(a) with total cholesterol (Lp(a) corrected levels), smoker status, hypertension, body mass index, diabetes, age at baseline, and sex (male),
and storage time. A linear mixed model was used to consider cohort heterogeneity.
BMI, body mass index.
Figure 2 Kaplan–Meier curves according to predefined Lp(a) categories for the endpoints MCE, CVD events, and total mortality. The 33rd per-
centile of LP(a) corresponds to the value of 5.3 mg/dL, the 66th percentile corresponds to the value of 14.1 mg/dL, and the 90th percentile corres-
ponds to the value of 43.5 mg/dL. P, P-value of log-rank test.
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..Similar differences were seen between a German and another
Finnish cohort by the group of Kronenberg et al (Florian Kronenberg,
personal communication).
Lp(a) levels are mainly genetically determined by the number of
kringle IV type 2 repeats which correlate strongly and inversely with
Lp(a) levels whereas the influence of nutrition or lifestyle is rather
weak.28 Further, Lp(a) levels are much higher in people with African
ancestry compared to Caucasians. It is conceivable that over time in-
habitants of Southern Europe have mixed more genetic characteris-
tics with people of African origin than inhabitants of Northern
Europe. Therefore, regional differences of Lp(a) levels in European
populations might be due to lower numbers of kringle IV type 2 re-
peats in Southern European populations compared to Northern
European populations. Interestingly, the regional differences of Lp(a)
did not lead to differences regarding the Lp(a)-associated cardiovas-
cular risk in different European regions. However, this issue has to be
subject of further studies.
Lp(a) as a marker of cardiovascular risk
Elevated Lp(a) levels have been demonstrated to be a marker of
increased cardiovascular risk for a broad spectrum of subgroups. As
the endpoint classification of CVD events was mainly driven by myo-
cardial infarction, risk estimates for the endpoints CVD events and
MCE are rather similar. The significant increase of the Lp(a)-
associated risk for MCE and CVD events for Lp(a) levels above the
66th percentile is in line with previous studies. Also, the magnitude of
the associations in our study is similar to others: The emerging risk
factors collaboration meta-analysis found after adjustment for cardio-
vascular risk factors a HR of 1.27 for myocardial infarction or fatal cor-
onary events for the top third vs. the lowest third of Lp(a) levels
which is comparable to our HRs for MCE of 1.30 and 1.49 for Lp(a)
levels in the 67–89th percentile and >_90th percentile compared to
the lowest third of Lp(a) levels.6 Using a lower-risk reference category
of Lp(a)-levels <22nd percentile Kamstrup and colleagues found
somewhat higher multivariable-adjusted HRs for myocardial infarction
with 1.6 for Lp(a) levels in the 67–89th percentile, 1.9 for 90–95th
percentile, and 2.6 for >_95th percentile.5 In addition to the percentile-
based analyses which are performed by the vast majority of Lp(a)
studies we applied the clinically important threshold of 50 mg/dL and
found a strong association for MCE and CVD events for Lp(a) levels
>_50 mg/dL compared to Lp(a) levels <50 mg/dL. This confirms the
desirable Lp(a) level of <50 mg/dL recommended by the guidelines.17
Figure 3 Cox regression analysis according to predefined Lp(a) categories (below 33rd percentile, 33rd-66th percentile, 67–89th percentile,
above the 90th percentile) for the endpoints MCE, CVD events, and total mortality for two models of adjustment Model 1 (red rhombus) —adjusted
for age, sex and cohort. Model 2 (blue rhombus)—adjusted for age, sex, cohort, smoking status, total cholesterol, diabetes, hypertension, and BMI. N
events for MCE = 2038, N events for CVD events = 2478, and N events for total mortality = 3978. HR (95% CI), hazard ratio with 95% confidence
interval.
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Figure 4 Subgroups analysis for a continuous version of cube root transformed Lp(a) for the endpoints MCE, CVD events, and total mortality.
Subgroups used: age (<65 vs. >_65 years), sex (men vs. women), smoking status, diabetes, hypertension, BMI (<30 vs. >_30), European region
(Southern, Central vs. Northern), and LDL (<160 mg/dL vs. >_160mg/dL). HR (95%CI), hazard ratio (95% confidence interval), P, P-value for HRs.
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The considerable size of the dataset allowed us to perform power-
ful subgroup analysis. The subgroup with the highest Lp(a)-associated
cardiovascular risk were n = 2785 individuals with diabetes represent-
ing 5.4% of the total study population, while other cardiovascular
high risk states did not influence the Lp(a)-associated cardiovascular
risk. In previous studies, the results regarding the Lp(a)-associated
risk in diabetic vs. non-diabetic individuals are heterogeneous or this
issue has not be addressed.6,29–31 Since the presence of diabetes cor-
related negatively with Lp(a) levels in our analysis and in other stud-
ies, the increased risk in individuals with diabetes cannot be explained
by higher Lp(a) levels in these individuals. Hence, there might be fac-
tors which induce a higher atherogenic or thrombogenic potency of
Lp(a) e.g. due to glycosylation as known from LDL in a diabetic
environment.32
In the present study, we found only slight NRI and C-Index change.
The issue whether Lp(a) improves cardiovascular risk prediction has
been addressed only by few studies yet. Comparability of reclassifica-
tion analyses is often limited due to different base models and risk
categories. Recently, Willeit and colleagues found a more relevant
NRI and increase of the C-index for addition of Lp(a) to Framingham
risk score and Reynolds risk score variables in 826 participants of the
Bruneck study.8 Our data and results are rather comparable to the
emerging risk factors collaboration analysis reporting only slight im-
provement of CVD prediction when adding Lp(a) to conventional
CV risk factors in 165 544 participants from 37 cohorts.33 It is con-
ceivable that in the emerging risk factors collaboration analysis and in
our study residual confounding of large-scale data may have weak-
ened the results compared to the more pronounced cardiovascular
risk prediction in the small, very precisely characterized cohort of the
Bruneck study. However, our results with only marginal risk predic-
tion improvement confirm the guideline recommendation to deter-
mine Lp(a) not routinely in the setting of primary prevention.
Comparison of Lp(a) levels to previous
studies
Due to non-standardization of Lp(a)-assays the comparability of ab-
solute Lp(a) levels in general is limited across different studies.
Therefore, the largest meta-analysis of 26 cohort studies using a wide
variety of different assays showed a range of Lp(a) medians between
3.0 and 23.0 mg/dL across the included studies.6 The present study,
using the same assay in a central laboratory, revealed a range of co-
hort specific median values of Lp(a) between 4.6 and 11.3 mg/dL.
One factor for the relatively low Lp(a) medians in our study could
have been the prolonged storage duration of blood samples.
However, the correlation of storage time as a technical variable and
Lp(a) levels was only modest and statistically not significant. We
noted comparable Lp(a) levels for cohorts within similar regions des-
pite large differences in the storage duration (Brianza MONICA 25
years, Moli-Sani 8 years, MATISS 21 years) (see Supplementary ma-
terial online, Table S2). Furthermore, the same Lp(a) assay used for
the present study was evaluated in fresh plasma samples of a
Northern Spanish population with a median of 25.3 nmol/L.15
Although the validity of a conversion from nmol/L to mg/dL is gener-
ally limited due to large differences of the molecular weight of Lp(a),
applying the mean conversion factor of 2.4 suggested by Marcovina
and colleagues34 to our measurements of stored samples results in a
median of 26.1 nmol/L in the Southern European cohorts of the pre-
sent study, which is comparable to the median of 25.3 nmol/L of
Simo and colleagues in fresh samples of a Northern Spanish
population.15
Strengths and limitations
Some strengths and limitations of the present study merit consider-
ation. Despite long-standing expertise in international standardization
of data collection and data harmonization in the MORGAM Data
Centre since 1984, resulting in excellent risk factor and endpoint val-
idation, we cannot exclude a potential contribution of residual con-
founding for some of the observed effects among the more than
56 000 individuals investigated in 7 European population-based co-
hort studies. Of these, some variables are missing in some cohorts
e.g. information on LDL and HDL values are not available for the
Caerphilly cohort.
On the one hand we present a large scale dataset of Lp(a) meas-
ured centrally with the same assay, but on the other hand differences
in storage duration among the included cohorts may have contrib-
uted to differences in the Lp(a) levels across populations. However,
the resulting effect appears rather minor without a significant correl-
ation for Lp(a) and storage duration. The leading cause for the re-
markable differences across European population with lower Lp(a)
levels in Northern European cohorts might be differences in the
prevalence of kringle IV type 2 repeats. However, as we cannot pro-
vide genetic data for our analyses, this issue remains hypothetical and
has to be addressed in future studies. Further, Lp(a) measurements
were not performed consecutively so that we cannot correct for re-
gression dilution bias. Despite the remarkable stability of Lp(a) this
could have led to an underestimation of risk estimates.35
Conclusion
In this large Lp(a) dataset on harmonized Lp(a) determination, we
observed a north–south gradient of Lp(a) levels across Europe with
lower Lp(a) levels in Northern European cohorts. Further, we could
confirm Lp(a) as a marker of cardiovascular risk in the European
population with an increasing cardiovascular risk for Lp(a)-levels
above the 66th percentile. Individuals with diabetes had a particularly
high Lp(a)-associated risk. These results may lead to better identifica-
tion of target populations who might benefit most from future Lp(a)-
lowering therapies.
Supplementary material
Supplementary material is available at European Heart Journal online.
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